PT-141
Also known as Bremelanotide · Vyleesi
New
Reconstitution & dosing guide
10 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
PT141 · Not in current stock
$25 / vial
Prices per vial · Research use only · Not medical advice.
Melanocortin agonist approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women; also used off-label in men in clinics/forums.
How to picture it
PT-141 (bremelanotide) is a melanocortin agonist aimed at central pathways for sexual desire and arousal — brain circuits, not a local blood-flow drug like PDE5 inhibitors. Picture flipping a melanocortin switch in desire networks rather than dilating vessels in the periphery. That CNS targeting is the educational distinction from both tanning peptides and classic erectile-function agents.
Research focus & benefits
- Central sexual-arousal pathway research
- Melanocortin CNS signaling studies
- Clinical development history in desire/arousal indications
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
PT-141 (bremelanotide) acts on central melanocortin pathways rather than the vascular pathway targeted by PDE5 inhibitors. The approved product Vyleesi is an autoinjector for HSDD. Research and gray-market vials also circulate.
Mechanism
Primarily MC4R (and related) agonism in the CNS influencing sexual desire and arousal circuitry.
Research uses
- HSDD in premenopausal women (approved)
- Male sexual dysfunction exploratory use
- Melanocortin pharmacology
Research dosing notes
Approved product has specific pre-activity dosing limits per day/month. Nasal research versions differ and are not the approved product.
Half-life / kinetics
~2.7 hours (bremelanotide)
Common research routes
Reported considerations
- Nausea
- Flushing
- Headache
- Transient blood-pressure/heart-rate changes
- Hyperpigmentation with repeated use
Contraindications / cautions
- Uncontrolled hypertension
- Cardiovascular disease cautions
- Pregnancy
Common research stacks
- Sometimes discussed with low-dose PDE5 agents under medical care
Legal / access note
FDA-approved as Vyleesi for HSDD in premenopausal women. Other formulations/uses may be off-label or unapproved.